Light therapy could spare kidneys in rare cancer trial
Disease control
Ongoing
This study tests a drug called TOOKAD (padeliporfin) that is activated by light to destroy low-grade tumors in the kidney or ureter. About 100 adults with this rare cancer will receive the treatment in two phases, with follow-up for up to 4 years. The goal is to see if the therap…
Phase 3 • Sponsor: Steba Biotech S.A. • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC